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Abstract
Background: Although the Barcelona Clinic Liver Cancer (BCLC) staging system suggests that patients with stage B
hepatocellular carcinoma (HCC) should be treated with transcatheter arterial chemoembolization instead of surgical
treatment, recent studies indicated that the prognosis of surgical resection for patients with BCLC stage B HCC was
better than that of TACE. However, the portion of patients with stage B that will achieve better outcomes from
surgical treatment remains unclear. In this study, we identified risk factors that influence the prognosis of BCLC
stage B HCC after R0 surgical resection to determine whether some patients with stage B HCC may benefit more
from R0 resection than other patients and to provide a guideline to estimate the tendency.
Methods: The clinical data of 78 patients with BCLC stage B HCC after R0 surgical treatment within 11 years were
analyzed retrospectively, using relapse or death as the endpoint. Kaplan-Meier survival and Cox regression analyses
were used to study prognosis (disease-free survival, DFS and overall survival, OS) and independent risk factors.
Results: For all stage B patients, 1-, 2-, and 5-year DFS rates were 62.5, 36.4, and 16.6 %, respectively. Cumulative
tumor size >5.0 cm and tumor number ≥4 were independent prognostic risk factors for DFS. The 1-, 2-, and 5- year
DFS rates and OS rates of patients with at least one of these two factors were 49.0, 17.2, and 7.4 % (for DFS), and
78.6, 54.8, and 13.4 % (for OS), respectively, which were significantly lower than patients without these two factors
(77.8, 58.3, and 27.2 % for DFS, and 94.4, 83.3,and 51.8 % for OS, respectively, P < 0.01).
Conclusions: The analyses indicated that the outcomes of R0 resection were much better for patients with BCLC stage
B HCC with two or three tumors and cumulative tumor sizes of ≤5.0 but >3.0 cm than other patients with stage B.
Keywords: BCLC staging, Hepatocellular carcinoma, Prognosis, R0 surgical treatment, Risk factors
Background
Hepatocellular carcinoma (HCC) is one of the five most
common malignancies worldwide. Each year, more than
690,000 people die from liver cancer, and the number is
increasing every year [1]. HCC is also the third most fre-
quent cause of tumor-related death [2]. The clinical sta-
ging system of HCC has an important function for
selecting treatment modes and evaluating prognosis, and
in recent years, the Barcelona Clinic Liver Cancer (BCLC)
staging system has received more attention. According to
the BCLC staging system, only patients with very early
stage and stage A (early stage) HCC should undergo surgi-
cal resection, ablation, or liver transplantation. Patients
with stage B HCC should be treated with transcatheter ar-
terial chemoembolization (TACE) [3]. However, many
studies have indicated that for patients with BCLC stage B
HCC, the prognosis of surgical resection is better than
that of TACE [4–7], indicating that it is feasible and
applicable for some patients with BCLC stage B HCC to
undergo R0 section. However, the portion of patients with
stage B that will achieve better outcomes from surgical
treatment remains unclear. Moreover, the standard
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indicators or influencing risk factors for selection of HCC
patients with stage B toward surgical resection have not
yet been established. Therefore, study of the risk factors
for prognosis of BCLC stage B after surgical treatment has
profound significance in forming a guideline for clinical
treatment of this sort of patients. Clarification of major
factors influencing curative efficiency will enable clinicians
to estimate whether a patient with BCLC stage B HCC
may achieve a better prognosis from R0 resection and
identification of those patients with non-improved out-
comes should be more carefully monitored after resection.
This study aims to provide surgeons with a guideline to




From 2001 to 2012, 827 patients with HCC underwent R0
hepatic resection in the Affiliated Hospital of Qingdao Uni-
versity, China and 78 patients suffered BCLC stage B HCC
disease. We declare that informed consents for the use of
their clinical data in this study were obtained from all par-
ticipants or their next of kin before follow up and before
the study began. We thank them a lot for their consent of
this study. BCLC staging was determined using liver ultra-
sonography or computed tomography (CT) and thorough
clinical assessment. All the patients had 2–5 cancerous
nodules with a cumulative tumor size of >3.0 cm, a Child-
Pugh score of A-B, and performance status of 0, and thus,
were classified as BCLC stage B. Pathological diagnoses
were made for all patients. There were 66 men and 12
women (ratio 5.5:1) and their age ranged 33–80 years old,
with an average of 55.9 years. The clinicopathological fea-
tures of the 78 patients are shown in Table 1. The collec-
tion of clinical data was approved by the Ethic Committee
of Affiliated Hospital of Qingdao University.
Surgical methods
All 78 cases underwent liver resection in accordance
with the Couinaud segmentation method to implement
hepatic segmentectomy or combined resection for adja-
cent liver segments (anatomical resection) or partial
hepatectomy containing tumor (nonanatomical resec-
tion). R0 hepatic resection means there were no residual
cancer cells present in the surgical margin when checked
Table 1 Clinicopathological features of 78 patients with Barcelona Clinic Liver Cancer stage B hepatocellular carcinoma
Factors Median (range or proportion)
Sex (male/female) 66:12 (84.6 %:15.4 %)
Age (years) 56.0 (33–80)
Alcohol consumption (no/yes)a 56:20 (73.7:26.3)
Preoperative TACE (no/yes) 67:11 (85.9 %:14.1 %)
HBsAg (negative/positive) 7:71 (9.0 %:91.0 %)
Anti-HCV (negative/positive) 76:2 (97.4 %:2.6 %)
ALT (U/L) 45.5 (12–191)
GGT (U/L) 49.5 (15–395)
Child–Pugh Classification (A/B) 76:2 (97.4 %:2.6 %)
Cirrhosis (no/yes) 5:73 (6.4 %:93.6 %)
Portal hypertension (no/yes) 65:13 (83.3 %:16.7 %)
Liver resection range (hepatic segment) 2 (1–4)
Resection margin (mm)a 5 (0–30)
Anatomical resection (yes/no) 18:60 (23.1 %:76.9 %)
Hepatic inflow occlusion (no/yes) 33:45 (42.3:57.7)
Intraoperative blood loss (mL) 300 (100–3500)
Blood transfusion (mL) 0.0 (0–1100)
Preoperative alpha-fetoprotein (μg/L) 17.8 (1.1–1211.0)
Cumulative tumor size (cm) 5.0 (2.5–20.0)
Tumor number 3 N
Differentiation (high/middle and low/necrosis) 3:73:2 (3.8 %:93.6 %:2.6 %)
Liver capsule invasion (no/yes) 12:66 (15.4 %:84.6 %)
ALT alanine aminotransferase, GGT gamma glutamyltransferase, HBsAg hepatitis B surface antigen
aSome patients lack data
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microscopically and no tumor visible with the naked
eyes.
Follow-up study
Serum alpha-fetoprotein, liver function tests, liver ultra-
sonography or CT and lung CT scan were performed
monthly for 3 months after surgical resection. The time
of recurrence after resection was adjudged by the presence
of clear masses on imaging examination. The follow-up
ended on 31 December 2015 or when patients died. The
median follow-up time was 31.4 months (ranging 3.3–
113.2 months).
Statistical analysis
All the data were statistically analyzed with SPSS Statistics
software for Windows, Version 13.0 (SPSS Inc., Chicago,
IL, USA). The Kaplan-Meier survival analysis (log-rank
test) was used to analyze disease-free survival (DFS) and
overall survival (OS). The factors with P < 0.05 were
enrolled in the Cox regression hazard model. P < 0.05 was
considered significant.
Results
Risk factors for DFS and OS
Seventy-eight patients with BCLC stage B HCC under-
went R0 hepatic resection. The OS rates for1, 2 and
5 years were 85.9, 67.9 and 29.8 %, respectively; the
median OS was 35.0 months [95 % confidence interval
(CI) = 29.4–40.6 months]. The DFS rates for 1, 2 and
5 years were 62.5, 36.4 and 16.6 %, respectively; and the
median DFS was 15.0 months (95 % CI = 10.7–
19.3 months).
In Table 2, we analyzed the relation of selected factors
with the DFS with Kaplan-Meier analysis. The result
showed that cumulative tumor size >5.0 cm and tumor
number ≧4 were important risk factors that significantly in-
fluenced DFS (P < 0.01). Then the two factors were enrolled
into Cox regression hazard model analysis which showed
that the cumulative tumor size and tumor number were
two significant independent risk factors for DFS (P < 0.05).
Relationship between recurrence and tumor number
Patients with BCLC stage B HCC were divided into three
groups according to tumor numbers which included 2, 3
Table 2 Factors influencing disease-free survival (DFS) for patients with Barcelona Clinic Liver Cancer stage B hepatocellular carcinoma
after R0 resection
Factors Kaplan–Meier analysis Cox regression hazard model
Median DFS (mo) P value HR(95 % CI) P value
Sex (male/female) 15.0/13.0 0.771
Age (≤60/>60 years) 15.0/13.0 0.530
Alcohol consumption (no/yes)a 15.0/18.0 0.463
Preoperative TACE (no/yes) 13.0/33.0 0.058
HBsAg (negative/positive) 8.0/18.0 0.267
Anti-HCV (negative/positive) 15.0/11.4 0.529
ALT (≤50/>50 U/L) 23.0/11.4 0.076
GGT (≤64/>64 U/L) 19.0/13.0 0.096
Child–Pugh classification (A/B) 15.0/5.7 0.288
Cirrhosis (no/yes) 25.0/15.0 0.317
Portal hypertension (no/yes) 15.0/23.0 0.769
Liver resection range (≤2/>2 segments) 17.0/8.0 0.084
Resection margin (<5/≥5 mm)a 13.0/19.0 0.573
Anatomical resection (yes/no) 14.6/15.0 0.783
Hepatic inflow occlusion (no/yes) 13.0/19.0 0.223
Intraoperative blood loss (≤1000/>100 mL) 18.0/13.0 0.282
Blood transfusion (yes/no) 17.0/15.0 0.732
Preoperative alpha-fetoprotein (≤20/>20 μg/L) 14.6/18.0 0.273
Cumulative tumor size (≤5/>5 cm) 25.0/13.0 0.009 1.685 (1.011–2.808) 0.045
Tumor number (≤3/≥4) 23.0/10.1 0.000 2.681 (1.506–4.770) 0.001
Differentiation (high/middle and low/necrosis) 24.0/15.0/19.2 0.671
Liver capsule invasion (no/yes) 13.0/17.0 0.882
aSome patients lacked data
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and more than 4 tumors, respectively. Kaplan-Meier survival
analysis was used to analyze the DFS for the three groups.
The median DFS time and the DFS rate for1, 2 and 5 years
decreased as tumor number increased (P < 0.01; Table 3).
Then, the receiver operating characteristic (ROC) curve
was applied for further analysis. The tumor number was
regarded as a test variable while the recurrence a state vari-
able. The area under the curve was 69.4 % (P = 0.024) and
the Youden index was 2.5 (specificity = 78.6 %, sensitivity =
56.3 %) (Fig. 1). We took the tumor number of 3 as the
critical value according to the Youden index. The 1-, 2-,
and 5-year DFS rates for the patients with tumor number ≤
3 (56 cases) and ≥4 (22 cases) were 71.4, 48.2, and 23 %
(for number ≤3), and 38.5, 4.8 and 0 % (for number ≥4),
respectively (P = 0.000) (Fig. 2). These analytic data clearly
indicate that the patients with 2 to 3 tumor number sur-
vived better with much lower recurrence rates than those
with tumor number ≥4.
Relationship between recurrence and tumor size
On the basis of the cumulative tumor size, patients were
divided into two groups, ≤5 cm (45 cases) and > 5 cm (33
cases). Kaplan-Meier analysis was performed to analyze the
DFS for the patients in the two groups. The 1-, 2- and 5-year
DFS rates were 70.6 , 50.1 and 22 % for the ≤5 cm group, and
51.5, 18.2 and 9.1 % for the > 5 cm group, respectively (P =
0.009, Fig. 3), indicating that the patients with cumulative
tumor size ≤5 but >3 cm showed significant lower recur-
rence rates than those with cumulative tumor size > 5 cm.
Comparison of DFS and OS between high-risk and
non-high-risk groups
Patients with tumor number ≥4 and cumulative tumor
size >5 cm were classified as the high-risk group (42
cases) while the other 36 patients as the non-high-risk
group. Kaplan-Meier survival analysis was performed to













2 39 28.8 76.9 53.8 23.1 0.001
3 17 19.0 58.8 25.3 22.1
≥4 22 10.1 38.5 4.8 0.0
Fig. 1 ROC curves of tumor number and recurrence
Fig. 2 Disease-free survival (DFS) curves of tumor number ≤3 and ≥4.
The upper curve represents DFS of patients with ≤3 tumors, while the
lower curve represents DFS of patients with ≥4 tumors
Fig. 3 Disease-free survival (DFS) curves of cumulative tumor size ≤5 cm
and >5 cm. The upper curve represents DFS of patients with a cumulative
tumor size of ≤5.0 cm, while the lower curve represents DFS of patients
with a cumulative tumor size >5.0 cm
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analyze the DFS. For patients in the high-risk and non-
high-risk groups, the 1-, 2-, and 5-year DFS rates were
49, 17.2 and 7.4 (for high-risk), and 77.8, 58.3 and
27.2 % (for non-high-risk), respectively (P = 0.001); the
OS rates at 1, 2. and 5 years were 78.6, 54.8 and 13.4 %
(for high-risk), and 94.4, 83.3 and 51.8 % (for non-
high-risk), respectively (P = 0.000) (Fig. 4). The signifi-
cance of the analytic results was in line with those in
3.2 and 3.3 sections, i.e., the recurrence rates of the
non-high-risk group were significantly lower than
those of the high-risk group.
Discussion
Tumor recurrence after resection is an important factor
affecting the prognosis of patients with HCC. The BCLC
staging system was proposed in 1999 by Llovet et al. [8]
and modified by the American Association for the Study
of Liver Diseases in 2005 [9]. This staging system
Fig. 4 Disease-free survival (DFS) and overall survival (OS) curves of high-risk and non-high-risk group. The upper curves represent the DFS and OS of
the non-high-risk group, while the lower curves are DFS and OS of the high-risk group
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comprehensively considers tumor size and number, vas-
cular invasion, liver function, and general condition. It
has been accepted worldwide at present. The system rec-
ommends that patients with stage B HCC should be
treated with TACE. However, many studies have indi-
cated that for patients with BCLC stage B HCC, the
prognosis for surgical resection treatment is superior to
that for TACE. For example, from 171 patients with
BCLC stage B HCC, Lin [5] found that the 1-, 2- and 3-
year OS rates after surgical resection or TACE was 83,
62 and 49 % or 39, 5 and 2 %, respectively. The progno-
sis of surgical resection was obviously better than that of
TACE.
Considering that patients with BCLC stage B HCC fre-
quently have multiple tumors with or without vascular in-
vasion and intrahepatic metastasis, we think that it is
necessary to explore further the indicators of surgical re-
section for this stage HCC to obtain a better prognosis. In
this study, we identified that tumor number ≥4 and cumu-
lative tumor size >5 cm were independent risk factors in-
fluencing the prognosis of BCLC stage B HCC after R0
liver resection. Median DFS and OS in patients with these
two factors were 12.0 and 25.0 months, respectively,
which were significantly lower than those of patients with
tumor number 2 or 3 and cumulative tumor size ≤5 cm
(31.0 and 67.0 months, P < 0.01). In keeping with our
current study, many studies have proved that tumor num-
ber [10–14] and tumor size [10, 11, 15–17] can affect
prognosis after resection of HCC. For example, Shah et al.
[10] discovered that multiple tumors and large tumor size
are independent risk factors of postoperative recurrence
of HCC.
It is clinically significant that tumor number and size
have been identified as two independent risk factors. The
blood supply of HCC is mainly from the hepatic artery
and portal vein. Therefore, large tumors always have a
more abundant blood supply, grow faster, break through
the capsule more easily and transfer to and infiltrate the
surrounding liver tissue readily. Large tumors also more
easily cause invasion of the portal vein, increasing the
probability of postoperative intrahepatic recurrence. Mul-
tiple tumors in the liver are mostly due to intrahepatic
metastasis, and an increase in tumor number usually indi-
cates more rapid metastasis. For these patients, even if the
visible tumors are totally removed, small metastases may
also be present in the liver, resulting in recurrence of
HCC, which is consistent with the finding of this study
that patients with HCC stage B with ≥4 tumors or a cu-
mulative tumor size of >5.0 cm had higher postoperative
recurrence rates.
Our study was limited by the small sample size and
regional area, which may not be representative of pa-
tients with BCLC stage B HCC in other areas. Moreover,
the follow-up period for some patients was relatively
short. Nonetheless, these patients were included in the
analysis because they meet the BCLC stage B-staging
standard, although they had many significant risk factors
reported already, e.g., age of >60 years; 4–5 nodules;
tumor size of >5.0 cm; significant amount of periopera-
tive blood loss; and much higher AFP, ALT, and GGT
levels than normal. In spite of these limitations, the re-
sults of this study revealed that both tumor number and
tumor size were the main staging indicators of BCLC
stage B HCC. Therefore, our study has important signifi-
cance in estimating clinical treatment and predicting the
prognosis to guide postoperative treatment.
Conclusions
This retrospective analysis suggests that patients with
BCLC stage B HCC having two or three tumors and a
cumulative tumor size of >3.0 cm but ≤5.0 cm achieved
better outcomes from R0 surgical resection than other
patients with stage B HCC.
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